Clinical characteristics and prognostic implications in patients with HER2-low breast cancer undergoing neoadjuvant chemotherapy: a retrospective cohort study

被引：0
|
作者：
Zheng, Ang [1 ]
He, Junlin [2 ]
Li, Muyao [1 ]
Yao, Fan [1 ]
Jin, Feng [1 ]
Chen, Bo [1 ]
Wang, Xin [2 ]
机构：
[1] China Med Univ, Hosp 1, Shenyang, Peoples R China
[2] China Med Univ, Shenyang, Peoples R China
来源：
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2025年 / 55卷
关键词：
HER2; Low; Breast Cancer;
D O I：
10.1016/j.lanwpc.2024.101378
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer
    Yi, Xiaoli
    Hu, Shasha
    Ma, Meili
    Huang, Dongshuai
    Zhang, Yan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (04) : 880 - 890
  • [32] Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Silvia Mihaela Ilie
    Nathalie Briot
    Guillaume Constantin
    Nicolas Roussot
    Alis Ilie
    Anthony Bergeron
    Laurent Arnould
    Françoise Beltjens
    Isabelle Desmoulin
    Didier Mayeur
    Courèche Kaderbhai
    Audrey Hennequin
    Clémentine Jankowski
    Marie Martine Padeano
    Helène Costaz
    Alix Amet
    Charles Coutant
    Bruno Coudert
    Aurélie Bertaut
    Sylvain Ladoire
    Breast Cancer, 2023, 30 : 997 - 1007
  • [33] Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer
    Xiaoli Yi
    Shasha Hu
    Meili Ma
    Dongshuai Huang
    Yan Zhang
    Clinical and Translational Oncology, 2024, 26 : 880 - 890
  • [34] Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
    Zhang, Huina
    Peng, Yan
    CANCERS, 2023, 15 (01)
  • [35] Refining the definition of HER2-low class in invasive breast cancer
    Atallah, Nehal M.
    Toss, Michael S.
    Green, Andrew R.
    Mongan, Nigel P.
    Ball, Graham
    Rakha, Emad A.
    HISTOPATHOLOGY, 2022, 81 (06) : 770 - 785
  • [36] Evaluating dynamic contrast-enhanced MRI for differentiating HER2-zero, HER2-low, and HER2-positive breast cancers in patients undergoing neoadjuvant chemotherapy
    Hu, Yangling
    Li, Meizhi
    Hu, Yalan
    Wang, Mengyi
    Lin, Yingyu
    Mao, Lijuan
    Wang, Chaoyang
    Shui, Yanhong
    Song, Yutong
    Wang, Huan
    Ji, Lin
    Che, Xin
    Shao, Nan
    Zhang, Xiaoling
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2025, 30 (01) : 132
  • [37] The impact of the HER2-low status on conditional survival in patients with breast cancer
    Ma, Teng
    Liu, Changgen
    Ma, Tianyi
    Sun, Xinyi
    Cui, Jian
    Wang, Lulu
    Mao, Yan
    Wang, Haibo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [38] Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
    Poeschke, Patrik
    Fasching, Peter A.
    Adler, Werner
    Ruebner, Matthias
    Beckmann, Matthias W.
    Hack, Carolin C.
    Heindl, Felix
    Hartmann, Arndt
    Erber, Ramona
    Gass, Paul
    CANCERS, 2023, 15 (19)
  • [39] Real-World Data on Pathological Response and Survival Outcomes After Neoadjuvant Chemotherapy in HER2-Low Breast Cancer Patients
    Guan, Dandan
    Shi, Qingyang
    Zheng, Yajuan
    Zheng, Chaopeng
    Meng, Xuli
    CLINICAL BREAST CANCER, 2024, 24 (05) : 463 - 472.e2
  • [40] Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer
    Viale, G.
    Basik, M.
    Niikura, N.
    Tokunaga, E.
    Brucker, S.
    Penault-Llorca, F.
    Hayashi, N.
    Sohn, J.
    Sousa, R. Teixeira de
    Brufsky, A. M.
    O'Brien, C. S.
    Schmitt, F.
    Higgins, G.
    Varghese, D.
    James, G. D.
    Moh, A.
    Livingston, A.
    de Giorgio-Miller, V.
    ESMO OPEN, 2023, 8 (04)
12345